A Phase 2a Study assessing the efficacy and safety of STN1013400 ophthalmic solution in patients with myopia

A phase 2a, randomized, evaluator-masked, placebo-controlled, parallel-group, multicenter study assessing the efficacy and safety of STN1013400 ophthalmic solution in subjects with mild or moderate myopia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031230110

Enrollment

Registered

2023-06-03

Start date

2023-05-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Interventions

High dose STN1013400 ophthalmic solution, low dose STN1013400 ophthalmic solution or placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Written informed consent from legally acceptable representative and assent from subject have been obtained. Cycloplegic objective spherical equivalent -1.0 to -6.0 D (-1.0 <=X<= -6.0) in both eyes. Patients with progressive myopia on refractive examination.

Exclusion criteria

Exclusion criteria: Patients who previously receive treatments for reducing myopia progression. Patients who are inappropriate as participants in this study in the opinion of the investigator or sub-investigator.

Design outcomes

Primary

Measure	Time frame
The change in objective spherical equivalent	—

Contacts

Public ContactYukie Migita

Santen pharmaceutical co.,ltd

clinical@santen.co.jp+81-6-4802-9341

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026